Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma

Stefano Mazzoleni, Gianni Bisogno, Alberto Garaventa, Giovanni Cecchetto, Andrea Ferrari, Guido Sotti, Alberto Donfrancesco, Enrico Madon, Letizia Casula, Modesto Carli

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Although > 90% of children with nonmetastatic rhabdomyosarcoma (RMS) achieve complete remission with current treatment, up to one-third of them experience a recurrence. Survival rates are not always poor in patients who develop recurrences; thus, prognostic factors are needed to tailor salvage treatment. METHODS. The current analysis included 125 children who were affected by localized RMS and were enrolled in 3 consecutive Italian protocols (RMS79, RMS88, and RMS96) who developed recurrences after complete remission. Patient, tumor, and treatment characteristics were studied in univariate and multivariate analyses to determine the independent significance of different factors. RESULTS. The median time from diagnosis to recurrence was 17.8 months. Most patients had local recurrences (72%). The 5-year overall survival (OS) rate was 28.3% ± 8.7%. Multivariate analysis identified 4 factors that were associated with poor survival: 1) alveolar subtype (relative risk [RR], 2.0), 2) parameningeal or "other" sites (RR, 2.6), 3) systemic recurrence (RR, 3.1), and 4) recurrence on therapy (RR, 2.3). The absence of any of these risk factors identified a "favorable risk" group (12% of patients) with a 5-year OS rate of 71.8% ± 23.5%. Patients with a single risk factor (32%) had an OS rate of 37.5% ± 17.2%. Combining patients with 0 or 1 risk factor, the OS rate was 66.5% in the subgroup who had not received radiotherapy compared with an OS rate of 30.3% in the subgroup who had received radiotherapy; this difference was significant (P = 0.03). CONCLUSIONS. The results of the current analysis demonstrated that groups with a different prognosis can be identified among patients with recurrent RMS. Patients with a nonalveolar histology, a primary site other than the parameningeal or "other" sites, local recurrence, and recurrence off therapy had a better prognosis. First-line treatment may have an impact on prognostic variables. In fact, patients who had no or only one risk factor and patients who had tumors with a nonalveolar histology benefited more from salvage therapy if they had not received radiotherapy for their initial treatment. These data may be useful in planning risk-adapted salvage protocols.

Original languageEnglish
Pages (from-to)183-190
Number of pages8
JournalCancer
Volume104
Issue number1
DOIs
Publication statusPublished - Jul 1 2005

Fingerprint

Rhabdomyosarcoma
Recurrence
Survival Rate
Salvage Therapy
Radiotherapy
Histology
Therapeutics
Multivariate Analysis
Neoplasms
Survival

Keywords

  • Nonalveolar histology
  • Prognostic factors
  • Recurrence
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. / Mazzoleni, Stefano; Bisogno, Gianni; Garaventa, Alberto; Cecchetto, Giovanni; Ferrari, Andrea; Sotti, Guido; Donfrancesco, Alberto; Madon, Enrico; Casula, Letizia; Carli, Modesto.

In: Cancer, Vol. 104, No. 1, 01.07.2005, p. 183-190.

Research output: Contribution to journalArticle

Mazzoleni, S, Bisogno, G, Garaventa, A, Cecchetto, G, Ferrari, A, Sotti, G, Donfrancesco, A, Madon, E, Casula, L & Carli, M 2005, 'Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma', Cancer, vol. 104, no. 1, pp. 183-190. https://doi.org/10.1002/cncr.21138
Mazzoleni, Stefano ; Bisogno, Gianni ; Garaventa, Alberto ; Cecchetto, Giovanni ; Ferrari, Andrea ; Sotti, Guido ; Donfrancesco, Alberto ; Madon, Enrico ; Casula, Letizia ; Carli, Modesto. / Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. In: Cancer. 2005 ; Vol. 104, No. 1. pp. 183-190.
@article{a2affbf3e4c844dab694464bdc146dd7,
title = "Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma",
abstract = "BACKGROUND. Although > 90{\%} of children with nonmetastatic rhabdomyosarcoma (RMS) achieve complete remission with current treatment, up to one-third of them experience a recurrence. Survival rates are not always poor in patients who develop recurrences; thus, prognostic factors are needed to tailor salvage treatment. METHODS. The current analysis included 125 children who were affected by localized RMS and were enrolled in 3 consecutive Italian protocols (RMS79, RMS88, and RMS96) who developed recurrences after complete remission. Patient, tumor, and treatment characteristics were studied in univariate and multivariate analyses to determine the independent significance of different factors. RESULTS. The median time from diagnosis to recurrence was 17.8 months. Most patients had local recurrences (72{\%}). The 5-year overall survival (OS) rate was 28.3{\%} ± 8.7{\%}. Multivariate analysis identified 4 factors that were associated with poor survival: 1) alveolar subtype (relative risk [RR], 2.0), 2) parameningeal or {"}other{"} sites (RR, 2.6), 3) systemic recurrence (RR, 3.1), and 4) recurrence on therapy (RR, 2.3). The absence of any of these risk factors identified a {"}favorable risk{"} group (12{\%} of patients) with a 5-year OS rate of 71.8{\%} ± 23.5{\%}. Patients with a single risk factor (32{\%}) had an OS rate of 37.5{\%} ± 17.2{\%}. Combining patients with 0 or 1 risk factor, the OS rate was 66.5{\%} in the subgroup who had not received radiotherapy compared with an OS rate of 30.3{\%} in the subgroup who had received radiotherapy; this difference was significant (P = 0.03). CONCLUSIONS. The results of the current analysis demonstrated that groups with a different prognosis can be identified among patients with recurrent RMS. Patients with a nonalveolar histology, a primary site other than the parameningeal or {"}other{"} sites, local recurrence, and recurrence off therapy had a better prognosis. First-line treatment may have an impact on prognostic variables. In fact, patients who had no or only one risk factor and patients who had tumors with a nonalveolar histology benefited more from salvage therapy if they had not received radiotherapy for their initial treatment. These data may be useful in planning risk-adapted salvage protocols.",
keywords = "Nonalveolar histology, Prognostic factors, Recurrence, Rhabdomyosarcoma",
author = "Stefano Mazzoleni and Gianni Bisogno and Alberto Garaventa and Giovanni Cecchetto and Andrea Ferrari and Guido Sotti and Alberto Donfrancesco and Enrico Madon and Letizia Casula and Modesto Carli",
year = "2005",
month = "7",
day = "1",
doi = "10.1002/cncr.21138",
language = "English",
volume = "104",
pages = "183--190",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma

AU - Mazzoleni, Stefano

AU - Bisogno, Gianni

AU - Garaventa, Alberto

AU - Cecchetto, Giovanni

AU - Ferrari, Andrea

AU - Sotti, Guido

AU - Donfrancesco, Alberto

AU - Madon, Enrico

AU - Casula, Letizia

AU - Carli, Modesto

PY - 2005/7/1

Y1 - 2005/7/1

N2 - BACKGROUND. Although > 90% of children with nonmetastatic rhabdomyosarcoma (RMS) achieve complete remission with current treatment, up to one-third of them experience a recurrence. Survival rates are not always poor in patients who develop recurrences; thus, prognostic factors are needed to tailor salvage treatment. METHODS. The current analysis included 125 children who were affected by localized RMS and were enrolled in 3 consecutive Italian protocols (RMS79, RMS88, and RMS96) who developed recurrences after complete remission. Patient, tumor, and treatment characteristics were studied in univariate and multivariate analyses to determine the independent significance of different factors. RESULTS. The median time from diagnosis to recurrence was 17.8 months. Most patients had local recurrences (72%). The 5-year overall survival (OS) rate was 28.3% ± 8.7%. Multivariate analysis identified 4 factors that were associated with poor survival: 1) alveolar subtype (relative risk [RR], 2.0), 2) parameningeal or "other" sites (RR, 2.6), 3) systemic recurrence (RR, 3.1), and 4) recurrence on therapy (RR, 2.3). The absence of any of these risk factors identified a "favorable risk" group (12% of patients) with a 5-year OS rate of 71.8% ± 23.5%. Patients with a single risk factor (32%) had an OS rate of 37.5% ± 17.2%. Combining patients with 0 or 1 risk factor, the OS rate was 66.5% in the subgroup who had not received radiotherapy compared with an OS rate of 30.3% in the subgroup who had received radiotherapy; this difference was significant (P = 0.03). CONCLUSIONS. The results of the current analysis demonstrated that groups with a different prognosis can be identified among patients with recurrent RMS. Patients with a nonalveolar histology, a primary site other than the parameningeal or "other" sites, local recurrence, and recurrence off therapy had a better prognosis. First-line treatment may have an impact on prognostic variables. In fact, patients who had no or only one risk factor and patients who had tumors with a nonalveolar histology benefited more from salvage therapy if they had not received radiotherapy for their initial treatment. These data may be useful in planning risk-adapted salvage protocols.

AB - BACKGROUND. Although > 90% of children with nonmetastatic rhabdomyosarcoma (RMS) achieve complete remission with current treatment, up to one-third of them experience a recurrence. Survival rates are not always poor in patients who develop recurrences; thus, prognostic factors are needed to tailor salvage treatment. METHODS. The current analysis included 125 children who were affected by localized RMS and were enrolled in 3 consecutive Italian protocols (RMS79, RMS88, and RMS96) who developed recurrences after complete remission. Patient, tumor, and treatment characteristics were studied in univariate and multivariate analyses to determine the independent significance of different factors. RESULTS. The median time from diagnosis to recurrence was 17.8 months. Most patients had local recurrences (72%). The 5-year overall survival (OS) rate was 28.3% ± 8.7%. Multivariate analysis identified 4 factors that were associated with poor survival: 1) alveolar subtype (relative risk [RR], 2.0), 2) parameningeal or "other" sites (RR, 2.6), 3) systemic recurrence (RR, 3.1), and 4) recurrence on therapy (RR, 2.3). The absence of any of these risk factors identified a "favorable risk" group (12% of patients) with a 5-year OS rate of 71.8% ± 23.5%. Patients with a single risk factor (32%) had an OS rate of 37.5% ± 17.2%. Combining patients with 0 or 1 risk factor, the OS rate was 66.5% in the subgroup who had not received radiotherapy compared with an OS rate of 30.3% in the subgroup who had received radiotherapy; this difference was significant (P = 0.03). CONCLUSIONS. The results of the current analysis demonstrated that groups with a different prognosis can be identified among patients with recurrent RMS. Patients with a nonalveolar histology, a primary site other than the parameningeal or "other" sites, local recurrence, and recurrence off therapy had a better prognosis. First-line treatment may have an impact on prognostic variables. In fact, patients who had no or only one risk factor and patients who had tumors with a nonalveolar histology benefited more from salvage therapy if they had not received radiotherapy for their initial treatment. These data may be useful in planning risk-adapted salvage protocols.

KW - Nonalveolar histology

KW - Prognostic factors

KW - Recurrence

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=20544459342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544459342&partnerID=8YFLogxK

U2 - 10.1002/cncr.21138

DO - 10.1002/cncr.21138

M3 - Article

C2 - 15895378

AN - SCOPUS:20544459342

VL - 104

SP - 183

EP - 190

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -